Thyroid:放射性碘与长期甲巯咪唑治疗毒性多结节性甲状腺肿的疗效比较

2019-07-06 xing.T 网络

由此可见,长期、低剂量MMI治疗60-100个月是治疗TMNG安全有效的方法,其疗效并不逊色于RAI治疗。

近日,甲状腺疾病领域权威杂志Thyroid上发表了一篇研究文章,该研究旨在比较长期甲巯咪唑(MMI)和放射性碘(RAI)治疗毒性多结节性甲状腺肿(TMNG)的有效性和安全性。

在这项随机、平行组试验中,130名连续就诊的、年龄<60岁和未治疗的TMNG患者入选并随机分为长期MMI治疗组或RAI治疗组。两组患者随访60-100个月,MMI和RAI组的中位持续时间分别为72和84个月。 

在MMI组和RAI组中,分别有12名和11名患者因副作用被排除,他们选择了其他治疗方式而未返回研究进行随访;53和54名患者分别完成了60-100个月的研究。在MMI组中,两名患者(3.8%)出现亚临床甲状腺功能减退症,51名患者(96.2%)在研究结束前仍保持甲状腺功能正常。在连续MMI治疗的第一年、第三年和第五年,维持甲状腺功能正常的MMI剂量为每日6.3±2.0、4.5±0.9和4.1±1.0mg。一名患者肝酶升高,三名患者在前三个月出现皮肤反应,但治疗后4至100个月没有发生MMI的不良反应。在RAI组中,22例(41%)出现甲状腺功能减退,12例(22%)出现持续或复发甲状腺功能亢进,20例(37%)在接受16.7±2.7 mCi 131I治疗后甲状腺功能正常。

由此可见,长期、低剂量MMI治疗60-100个月是治疗TMNG安全有效的方法,其疗效并不逊色于RAI治疗。 

原始出处:

Fereidoun Azizi,etal.Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment.Thyroid.2019.https://www.liebertpub.com/doi/10.1089/thy.2018.0397

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693582, encodeId=2cde169358239, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Mon Jun 01 23:59:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705174, encodeId=77bd1e05174e3, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Sun Nov 03 03:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395432, encodeId=ddac13954328d, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 08 05:59:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032213, encodeId=5a181032213ab, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Jul 06 17:59:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693582, encodeId=2cde169358239, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Mon Jun 01 23:59:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705174, encodeId=77bd1e05174e3, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Sun Nov 03 03:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395432, encodeId=ddac13954328d, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 08 05:59:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032213, encodeId=5a181032213ab, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Jul 06 17:59:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693582, encodeId=2cde169358239, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Mon Jun 01 23:59:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705174, encodeId=77bd1e05174e3, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Sun Nov 03 03:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395432, encodeId=ddac13954328d, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 08 05:59:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032213, encodeId=5a181032213ab, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Jul 06 17:59:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693582, encodeId=2cde169358239, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Mon Jun 01 23:59:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705174, encodeId=77bd1e05174e3, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Sun Nov 03 03:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395432, encodeId=ddac13954328d, content=<a href='/topic/show?id=504f5e36317' target=_blank style='color:#2F92EE;'>#放射性碘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57363, encryptionId=504f5e36317, topicName=放射性碘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 08 05:59:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032213, encodeId=5a181032213ab, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Jul 06 17:59:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-07-06 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

JCEM:甲状腺癌患者放射性碘相关的克隆性造血常见且与存活率降低相关

由此可见,RAI与CH的高患病率相关,CH是血液系统恶性肿瘤的前兆状态。这项研究的意义可能有助于识别接受RAI治疗风险可能超过受益的甲状腺癌的患者的CH。

Int J Cancer:放射性碘治疗甲状腺癌女性,几乎不影响未来的生育能力

放射性碘治疗( radioactive iodine ,RAI)是指口服一定量的131碘后,因为甲状腺细胞对碘化物具有特殊的亲和力,所有碘131能被甲状腺大量吸收,具有损害作用的放射131碘能种入甲状腺组织中,131碘在衰变为131氙时,能放射出β射线(占99%)和γ射线(占1%)。前者的有效射程仅有0.5~2毫米,能选择性地破坏甲状腺腺泡上皮而不影响邻近组织,甲状腺组织能受到长时间的集中照射,其

ASCO 2014:放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究

第50届美国临床肿瘤学会年会(ASCO2014)正在美国芝加哥召开。芝加哥——当地时间5月31日新闻发布会的重头戏是针对常见、难治性癌症的4项新型靶向药物的临床研究。据ASCO">ASCO新闻稿报道,这4项在研药物的临床研究分别针对晚期卵巢癌、肺癌、慢性淋巴细胞白血病(CLL)和甲状腺癌,均获得了阳性结果,提示能延缓疾病进展并且能使复发或者对当前治疗耐药患者的生存得以改善。

JCEM:低危分化型甲状腺癌患者应不应该接受放射性碘?

大家都知道目前的指南并不支持常规放射性碘(RAI)消融治疗低位分化型甲状腺癌(DTC)。为了评估RAI消融应用最新阶段的趋势,Ki Wan Park等人进行了一项研究,并把研究结果发表在近日的JCEM杂志上。